Profile

Ron Gibson, MD, PhD

Ron Gibson, MD, PhD

Pulmonary and Sleep Medicine, Cystic Fibrosis Research

On staff since November 1987

Children's Title: Director, Cystic Fibrosis Center; Co-Director, Cystic Fibrosis Therapeutic Development Center; Director, Pediatric Pulmonary Fellowship

Academic Title: Professor

Research Center: Center for Clinical and Translational Research

Ronald L. Gibson, MD, PhD, is Director of the Cystic Fibrosis (CF) Center, Director of the Pediatric Pulmonary Fellowship program, and attending physician at Seattle Children’s Hospital; he is a Professor in the Department of Pediatrics at the University of Washington School of Medicine. He earned his MD and PhD at Washington University in St. Louis. He completed pediatrics residency training and a fellowship in pediatric pulmonology at the University of Washington.

He is committed to high-quality, multidisciplinary patient care, small group teaching, research and the acquisition of new knowledge. His primary research focus is on early events in the pathogenesis of lung disease in CF, with a focus on the risk factors for and the treatment of Pseudomonas aeruginosa airway infections in young children with cystic fibrosis (CF). As a co–principal investigator of the university’s CF Translational Therapeutic Development Center, he has been lead and co-investigator for several phase I to phase III clinical trials involving novel antimicrobial agents, anti-inflammatory compounds and modulators of ion transport. Dr. Gibson is also director of the clinical core of the university’s CF research development program with the goal of catalyzing collaborations between local basic and clinical investigators.

Overview

Board Certification(s)

Pediatrics
Pediatric Pulmonology

Medical/Professional School

Washington University School of Medicine, St Louis

Residency

Pediatrics, University of Washington, Seattle

Fellowship

Pulmonary Disease, University of Washington, Seattle

Research Focus Area

Cystic Fibrosis

Awards and Honors

Award Name Award Description Awarded By Award Date
SEATTLE'S TOP DOCTOR - 2014 Seattle Metropolitan Magazine 2014
SEATTLE MAGAZINE TOP DOCTOR - 2014 Seattle Magazine 2014
Seattle's Top Doc Seattle Met Magazine 2013
Seattle Magazine Top Doctor - 2013 Seattle Magazine 2013
U.S. News Top Doctor U.S. News and World Report 2012
Seattle Magazine Top Doctor - 2012 Seattle Magazine Top Doctor - 2012 Seattle Magazine 2012
Seattles Top Doctors Seattle Magazine 2011
Seattles Top Doctors Seattle Magazine 2010
Nominee, Family Choice Award from Family Advisory Council Seattle Children's Hospital 2009
"Guide to America's Top Pediatricians" Consumer's Research Council of America 2009
Mentoring Award from the University of Washington School of Medicine Department of Pediatrics , University of Washington 2008
Selected to Best Doctors in America Best Doctors in America 2007 - 2009

Publications

  • Emerson J, Cochrane E, McNamara S, Kuypers J, Gibson RL, Campbell AP
    Home Self-Collection of Nasal Swabs for Diagnosis of Acute Respiratory Virus Infections in Children With Cystic Fibrosis.
    Journal of the Pediatric Infectious Diseases Society , 2013 Dec. : 2(4)345-351
  • Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW, EPIC, ESCF Investigators
    Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
    Pediatric pulmonology , 2013 Oct. : 48(10)943-53
  • Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW, EPIC, ESCF Investigators
    Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.
    Pediatric pulmonology , 2013 Oct. : 48(10)943-53
  • Guo DC, Regalado E, Casteel DE, Santos-Cortez RL, Gong L, Kim JJ, Dyack S, Horne SG, Chang G, Jondeau G, Boileau C, Coselli JS, Li Z, Leal SM, Shendure J, Rieder MJ, Bamshad MJ, Nickerson DA, GenTAC Registry Consortium, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project, Kim C, Milewicz DM
    Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections.
    American journal of human genetics , 2013 Aug. 8 : 93(2)398-404
  • Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR
    Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2013 Aug. : 57(3)384-91
  • Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, Guo S, Gonzalez M, Hedges DJ, Robertson PD, Krumm N, Nickerson DA, Hershberger RE, National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team
    Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy.
    Circulation. Cardiovascular genetics , 2013 Apr, : 6(2)144-53
  • Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Rieder MJ, Altshuler D, Shendure J, Nickerson DA, Bamshad MJ, NHLBI Exome Sequencing Project, Akey JM
    Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants.
    Nature , 2013 Jan. 10 : 493(7431)216-20
  • O'Connor TD, Kiezun A, Bamshad M, Rich SS, Smith JD, Turner E, NHLBIGO Exome Sequencing Project, ESP Population Genetics, Statistical Analysis Working Group, Leal SM, Akey JM
    Fine-scale patterns of population stratification confound rare variant association tests.
    PloS one , 2013 : 8(7)e65834
  • Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL, EPIC Study Group
    Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Sept. : 11(5)446-53
  • Rosenfeld M, Bernardo-Ocampo C, Emerson J, Genatossio A, Burns J, Gibson R
    Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Sept. : 11(5)456-7
  • Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B
    Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 Aug. 31
  • Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC, National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project, Lung GO, Gibson RL, Bamshad MJ
    Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Nature genetics , 2012 July 8 : 44(8)886-9
  • Quon BS, Patrick DL, Edwards TC, Aitken ML, Gibson RL, Genatossio A, McNamara S, Goss CH
    Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2012 May : 11(3)216-22
  • Burns JL, Emerson J, Kuypers J, Campbell AP, Gibson RL, McNamara S, Worrell K, Englund JA
    Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings.
    Influenza and other respiratory viruses , 2012 May : 6(3)218-23
  • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators
    Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    Pediatric pulmonology , 2012 Feb. : 47(2)125-34
  • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators
    Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    Pediatric pulmonology , 2012 Feb. : 47(2)125-34
  • Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB
    Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    The Journal of antimicrobial chemotherapy , 2011 Oct. : 66(10)2398-404
  • Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Early Pseudomonas Infection Control (EPIC) Investigators
    Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Archives of pediatrics & adolescent medicine , 2011 Sept. : 165(9)847-56
  • Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB
    Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2011 July : 10(4)234-42
  • Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL
    Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
    Pediatric pulmonology , 2011 Feb. : 46(2)184-92
  • Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ
    An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Pediatric pulmonology , 2010 Nov. : 45(11)1121-34
  • Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL, EPIC Study Group Participating Clinical Sites
    Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
    Pediatric pulmonology , 2010 Sept. : 45(9)934-44
  • Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH
    Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
    Pediatric pulmonology , 2010 Feb. : 45(2)127-34
  • Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR, Gene Modifier Study Group
    Genetic modifiers of liver disease in cystic fibrosis.
    JAMA : the journal of the American Medical Association , 2009 Sept. 9 : 302(10)1076-83
  • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group
    Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Contemporary clinical trials , 2009 May : 30(3)256-68
  • Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ
    Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Chest , 2009 May : 135(5)1223-32
  • Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW, Inhaled Tobramycin in Young Children Study Group, Cystic Fibrosis Foundation Therapeutics Development Network
    Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
    The Journal of pediatrics , 2009 Feb. : 154(2)183-8
  • Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR
    Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.
    Genetics in medicine : official journal of the American College of Medical Genetics , 2008 Dec. : 10(12)851-68
  • McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB
    Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2008 Nov. 1 : 178(9)921-8
  • Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL, AZLI Phase II Study Group
    A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Pediatric pulmonology , 2008 Jan. : 43(1)47-58
  • Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B
    Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Pediatric pulmonology , 2007 Sept. : 42(9)751-6
  • Treggiari MM, Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B
    Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Pediatric pulmonology , 2007 Sept. : 751-6
  • Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B
    No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
    American journal of respiratory cell and molecular biology , 2007 July : 37(1)57-66
  • Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B
    No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
    American journal of respiratory cell and molecular biology , 2007 July : 57-66
  • Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B
    Disease-specific reference equations for lung function in patients with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2005 Oct. 1 : 172(7)885-91
  • Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B
    Disease-specific reference equations for lung function in patients with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2005 Oct. 1 : 885-91
  • Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B, Cystic Fibrosis Foundation Therapeutics Development Network
    Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
    Pediatric pulmonology , 2005 Apr, : 39(4)339-48
  • Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B
    Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
    Pediatric pulmonology , 2005 Apr, : 339-48
  • Ron Gibson, MD, PhD
    Abstracts - Available upon request

Presentations

Presentations Title Event Location Date
Comparison of exome variants from phenotype extremes to a large population-based sample identifies CAV2 and TMC6 as interacting modifiers of chronic Pseudomonas infection in cystic fibrosis North American Cystic Fibrosis Conference Salt Lake City, Utah 2013

Research Funding

Grant Title Grantor Amount Award Date
Early MRSA Therapy in CF- culture based vs observant therapy (treat or observe) (STAR-too) Cystic Fibrosis Foundation
A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) Versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients MPex
I Change Adherence and Raise Expectations Novartis
Early Intervention in CF Exacerbation NIH
Cystic Fibrosis Foundation National Patient Registry Cystic Fibrosis Foundation
Co-director, Clinical Core, P30 Translational Research Center to Expedite Novel Therapies in Cystic Fibrosis NIH
Director, Clinical Core, Cystic Fibrosis Research Development Program Cystic Fibrosis Foundation
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) NIH
CF EPIC Participation in the NHLBI Lung Cohorts Sequencing Project NIH
The EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of Pseudomonas aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (Protocol # EPIC-002) Cystic Fibrosis Foundation $
Comparison study of regulatory T cell phenotypes and function in blood samples from individuals with CF and healthy non-CF controls Cystic Fibrosis Foundation
A Phase 3, Blinded, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-105) Vertex
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (VX12-809-103 Vertex
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects with Cystic Fibrosis Who Have the R117H-CFTR Mutation (VX11-770-110) Vertex
An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis (VX08-770-105) Vertex
Role of Islet Amyloid and IL-1 Signaling in -cell Loss in Cystic Fibrosis Related Diabetes NIH
Cystic Fibrosis Bronchoalveolar Lavage Fluid Specimen Bank Cystic Fibrosis Foundation